Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma
Status:
Completed
Trial end date:
2008-06-30
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the
cancer. It may also stimulate the immune system in different ways and stop cancer cells from
growing. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving
lenalidomide together with melphalan may kill more cancer cells.
PURPOSE: This randomized phase II trial is studying the side effects and best dose of
lenalidomide when given together with melphalan and to see how well they work in treating
patients with multiple myeloma.